Overview

Inclisiran Effectiveness in China: a Pragmatic Randomized Trial

Status:
RECRUITING
Trial end date:
2026-01-30
Target enrollment:
Participant gender:
Summary
The current study will be conducted to evaluate the real-world effectiveness of inclisiran relative to standard of care (SoC) in Chinese patients with coronary heart disease (CHD), not only with the low-density lipoprotein cholesterol (LDL-C) change in 1 year, but also the LDL-C Test on Target for 1 year. This study further aims to assess the adherence, treatment patterns and satisfaction, and safety of inclisiran among Chinese patients.
Phase:
PHASE4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Standard of Care